Navigation Links
EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
Date:8/25/2009

WELLESLEY HILLS, Mass., Aug. 25 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the intellectual property offered for sale at the September 30, 2009 auction.

The PRX-00023 is a CNS Therapeutics Program in Phase 2b/3. It is a small molecule, oral 5HT1A Agonist for CNS disorders. It is well tolerated with superior side effect profile compared to other 5HT1A agonists, SSRIs, and SNRIs. It has an open IND, some drug inventory available.

The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Ky. , Jan. 16, 2017  Eurofins Genomics ... which will allow more customers to receive their primers ... premium or compromise in quality found with other providers. ... the United States at no additional fee. ... of routine genetic studies, including DNA sequencing, genotyping, site-directed ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global Biopolymers ... ... of 16.83% during the period 2017-2021. The report covers ... for 2017-2021. To calculate the market size, the report considers the revenue ... includes a a discussion of the key vendors operating in this market. ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... , VTI, Vertebral Technologies, Inc., announces the successful outcome of the first ... September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to live. ... drug combination that has stabilized Rosendahl’s disease and increased both the quantity and ...
Breaking Biology Technology:
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
Breaking Biology News(10 mins):